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Abstract. – OBJECTIVE: Coronavirus disease 
2019 (COVID-19) is a pandemic and leading cause 
of death. Beyond the deaths directly caused by 
the virus and the suicides related to the psy-
chological response to the dramatic changes as 
socioeconomic related to the pandemic, there 
might also be suicides related to the inflammato-
ry responses of the infection. Infection induces 
inflammation as a cytokine storm, and there is an 
increasing number of studies that report a rela-
tionship between infection and suicide.
MATERIALS AND METHODS: We searched 
the World Health Organization status report and 
the PubMed database for keywords (COVID-19, 
suicide, infection, inflammation, cytokines), and 
reviewed five cytokine pathways between suicide 
and inflammation using two meta-analyses and 
two observational studies starting from Novem-
ber 31, 2020, focusing on the relationship between 
suicide and inflammation by infection. First, we 
discussed existing evidence explaining the rela-
tionship between suicidal behaviors and inflam-
mation. Second, we summarized the inflammatory 
features found in COVID-19 patients. Finally, we 
highlight the potential for these factors to affect 
the risk of suicide in COVID-19 patients.
RESULTS: Patients infected with COVID-19 
have high amounts of IL-1β, IFN-γ, IP10, and 
MCP1, which may lead to Th1 cell response 
activation. Also, Th2 cytokines (e.g., IL-4 and 
IL-10) were increased in COVID-19 infection. In 
COVID-19 patients, neurological conditions, like 
headache, dizziness, ataxia, seizures, and oth-
ers have been observed.
CONCLUSIONS: COVID-19 pandemic can serve 
as a significant environmental factor contributing 
directly to increased suicide risk; the role of inflam-
mation by an infection should not be overlooked.
Key Words: 
COVID-19, Suicide, Infection, Inflammation, Cytokine. 
Introduction
Coronavirus disease 2019 (COVID-19) was 
first reported in December 2019 in China and 
has become a global pandemic resulting in 
approximately 761,779 deaths as of August 
16, 20201. Many clinical symptoms regarding 
COVID-19 have been investigated, however, 
knowledge beyond these symptoms, particular-
ly those psychologically related, remains lim-
ited. As such, the psychological perspective of 
suicide related to COVID-19 is an important is-
sue to be considered. A pandemic presents a sit-
uation associated with increased suicide risk2,3. 
Indeed, some cases related to COVID-19 have 
been reported. Factors, such as anxiety and un-
certainty, social isolation, and economic prob-
lems can explain a significant proportion of the 
increase in suicide risk related to the pandem-
ic4. However, inflammation caused by infection 
is another important factor to be considered.
Inflammatory conditions, like infections, 
can trigger depressive symptoms and are asso-
ciated with suicide. Studies5-7 report that there 
is a clear difference in cytokine levels such 
as IL-6, IL-1β, and IL-2 between suicidal and 
non-suicidal patients. These inflammatory cy-
tokines can be synthesized in the central ner-
vous system or communicate with the brain 
via many different mechanisms, including the 
kynurenine pathway, monoamine metabolism, 
and hypothalamic-pituitary-adrenal (HPA) ax-
is8. COVID-19 is also associated with a signif-
icant increase in cytokine levels, which might 
partly explain the suicide observed in some of 
the individuals who are infected9. 
Therefore, in this review, we focused on the 
relationship between suicide and inflammation 
by infection. We searched the World Health Or-
ganization status report and the PubMed data-
base for keywords (COVID-19, suicide, infec-
tion, inflammation, cytokines), and reviewed 
five cytokine pathways between suicide and 
inflammation using two meta-analyses and two 
observational studies starting from November 
31, 2020. First, we discussed existing evidence 
explaining the relationship between suicide 
and inflammation. Second, we summarized 
the inflammatory features found in COVID-19 
patients. Finally, we highlight the potential 
for these factors to affect the risk of suicide in 
COVID-19 patients.
Risk Factors Associated with Suicidality
Suicide is an important issue and a signif-
icant challenge for the global public health 
community10. In the US alone, 40,000 people 
die due to suicide every year, and according to 
the World Health Organization (WHO), global-
ly, this figure is estimated to be approximately 
800,0008,11. In fact, WHO estimates indicate an 
individual will die by suicide somewhere in the 
world every 40 seconds11. As rates continually 
rise across countries, suicide will remain a ma-
jor public health problem12. 
Inconsistency in the nomenclature has hin-
dered the progress in suicide research and the-
ory13. Suicide is defined as death caused by a 
self-directed injury behavior with the intent to 
die as a result of one’s action and the suicide 
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attempt is the nonfatal self-directed injurious 
behavior with the intent to die as a result14. 
In contrast, suicidality and suicidal behavior 
broadly describe the overarching terminolo-
gy that spans across to include suicidal ideas, 
plans, the process of preparation and attempts 
that may be fatal15,16. Thus, caution needs to be 
taken when selecting specific terms to address 
suicidality and associated behaviors. The fol-
lowing sections of this paper have maintained 
consistency in using the terminology as ad-
dressed above.   
To understand the complexity of suicidali-
ty, various models have been suggested, with 
most acknowledging the interplay between 
predisposing and precipitating risk factors. A 
seminal example includes the biopsychosocial 
model17,18. It takes a comprehensive view of sui-
cide risk and its related factors12. Predisposing 
factors, such as genetic vulnerabilities19, ear-
ly-life adversity and trauma20, and demograph-
ic characteristics (e.g., socioeconomic status)21, 
contribute to suicidality and can lead to lasting 
alterations in gene expression. Moreover, cer-
tain mechanisms can affect such predisposing 
factors. For example, the increase in vulnera-
bility to stresses and developmental (also called 
psychological) factors such as core beliefs, per-
sonality traits, and cognitive deficits, can medi-
ate the link between predisposing factors and 
suicidality16. The other form of factors, those 
called precipitating or proximal, include events 
preceding the onset of the disorder, or in this 
case, suicidal behavior. That is, previous expe-
riences, (e.g., substance use, or interpersonal, 
occupational, financial, or physical stressors), 
or conditions (e.g., those psychological, so-
cioeconomic, and environmental, as well as 
pre-existing psychiatric disorders), can prompt 
suicidal behavior22. As posited in the biopsycho-
social model, these forms of both predisposing 
and precipitating factors can interact and elicit 
one’s vulnerability to suicide ideation, suicide 
attempt(s), and ultimately, suicide14. 
Pandemics and Suicidality
Previous pandemics have been found to be 
associated with an increase in suicide risk. 
In 2003, a severe acute respiratory syndrome 
(SARS) outbreak in Hong Kong was associat-
ed with increased suicide risk in older people23. 
Further studies2,3 of quarantined populations 
amidst pandemic conditions have indicated 
psychological difficulties and suicide attempts 
among hospitalized patients. Such behavior 
(i.e., increased risk for suicide) may be driven 
by several factors, including 1) anxiety and un-
certainty, 2) social isolation, and 3) economic 
problems4,24. First, it is known that individuals 
with underlying diseases or low resilience may 
exhibit suicidal ideation and attempt suicide 
when experiencing anxiety and uncertainty25. 
This was the case during the 2003 SARS out-
break, where these factors led to an increase in 
suicide among older adults23. Second, pandem-
ics often isolate people from society, which may 
be a situation that they have not experienced 
before. This sense of isolation can negatively 
affect individuals’ psychological well-being re-
gardless of the presence of disease4. Third and 
lastly, epidemics also have a negative impact on 
many businesses, which leads to temporary or 
permanent loss of income. Such financial wor-
ries have been shown to be associated with a 
loss of self-esteem, despair, depression, and 
substance abuse amongst others26. Moreover, a 
low income may reduce accessibility to psychi-
atric management. As a result, individuals with 
underlying diseases or vulnerability (socially 
or economically) may be more likely to attempt 
or commit suicide4. 
Regarding recent circumstances, the 
COVID-19 pandemic, which began in December 
2019, has spread precipitously worldwide. On 
March 11, 2020, the WHO declared COVID-19 
to be a pandemic. As extant epidemics have ex-
hibited increases in suicide risk, COVID-19 is 
no exception. In line with previous pandemics 
and epidemics, the potential effect of the cur-
rent COVID-19 pandemic on mental health is 
profound with an expected increase in anxiety 
and depression as well as suicide rates27. Fur-
thermore, just like the previous outbreaks, the 
consequence of social isolation is predicted to 
be associated with suicide rates28. However, the 
magnitude of the current COVID-19 pandemic 
far outweighs the prior epidemics with this be-
ing named as the worst pandemic in history29. 
Henceforth it is expected that social isolation, 
anxiety, fear of contagion, uncertainty, stress 
and other economic challenges may lead to 
greater exacerbation of stress and related disor-
ders, including suicidality, specifically among 
vulnerable people30.
According to Caballero-Dominguez et al31, 
7.6% of participants suffering COVID-19 pan-
demic reported a high suicide risk, which was 
associated with high perceived stress related to 
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COVID-19, risk of depressive episode, and in-
somnia. Also, as presented below, various cas-
es of suicide during this pandemic have been 
reported32-34. 
In one case study, a 34-year-old man was 
hospitalized in an isolation ward because of 
mild COVID-19 infection. While hospitalized, 
he had no respiratory symptoms or fever but 
complained of anxiety and insomnia. Though 
appropriate treatment was carried out, he at-
tempted suicide32. Not only in infected people 
but also in people with psychiatric disorders and 
other vulnerable individuals, suicidal behav-
iors have been reported during the COVID-19 
pandemic. In another case study, a 60-year-old 
woman with undiagnosed delusional disorder 
attempted suicide due to increased symptoms 
in response to the COVID-19 pandemic33.
Likewise, in a case study from India, a 
50-year-old man associated his viral illness 
with COVID-19 and thought he was infected 
with COVID-19. He was seized with fear and 
panic and finally ended his life by hanging 
himself34. 
Relationship between Inflammation 
and Suicide 
As mentioned above, multiple factors, in-
cluding genetic, experiential, psychological, 
clinical, sociological, and environmental fac-
tors, can increase the risk of suicide during an 
epidemic. However, the role of inf lammation 
in increasing the risk of suicide among those 
who are infected should also be considered. 
Such consideration is critical, given the com-
plex, multiplicative nature of factors leading 
to suicidality, as well as the severity of out-
come (i.e., an untimely loss of life).
Several conditions, including infection, can 
cause inf lammation, which can play a critical 
role in the pathophysiology of suicidal behav-
ior. Some authors35 suggest that there may be 
an association between suicidal behavior and 
inf lammatory cytokines. Studies in patients 
who received interferon (IFN)-based or in-
terleukin (IL)-2 immunotherapy showed that 
inf lammation can induce depressive symp-
toms which is related to suicidal behavior36,37. 
Following this seminal work, multiple stud-
ies have shown differences in cytokine levels 
between those who did and did not complete 
suicide. Isung et al5 reported that neuropro-
tective cytokine IL-8 levels in cerebrospinal 
f luid (CSF) were lower in those who attempted 
suicide compared to healthy controls, and this 
finding demonstrates impaired control of the 
immune system in suicidal patients. Pandey et 
al6 found that mRNA and protein levels of IL-
1β, IL-6, and tumor necrosis factor (TNF)-α 
were increased in post-mortem brain tissue 
from teenage suicide victims. Another study7 
also reported that suicide attempters show in-
creased levels of IL-6 and TNF-α, while IL-
2 levels were decreased. Additionally, there 
were clear differences in the immune response 
between suicidal and non-suicidal patients. 
One study found increased IL-6 production, 
as well as an imbalance in helper T-cell type 1 
(Th1) & helper T-cell type 2 (Th2) with a shift 
toward Th1 in non-suicidal major depression 
disorder (MDD) patients. Conversely, suicid-
al MDD patients were related to a decrease in 
IL-2 production38 and an elevation of Th2 ex-
pression in the orbitofrontal cortex39. Another 
study39 reported increased IL-4 and IL-13 ex-
pression in suicide victims, which suggested 
1) heightened Th2 cytokine expression, and 2) 
their mRNA transcripts exist in the brains of 
suicided people. Exposure and sensitization 
to aeroallergens also explain the relationship 
between suicide and T cell response. This in-
duces increased Th2 cytokine expression and 
increases the risk of suicide through several 
pathways40. 
Two meta-analyses41,42 reviewed studies 
related to cytokines and suicidality. Using a 
sample of 18 studies, Black and Ducasse found 
that high plasma levels of IL-6, IL-1β, and low 
IL-2 were reported in patients with suicidali-
ty. IL-1β and IL-6 levels were also elevated in 
post-mortem brain tissue of those who com-
pleted suicide whereas a decrease in IL-8 CSF 
levels were reported in patients with suicidal-
ity. In addition, using 11 studies, Ducasse et 
al42 analyzed the levels of 6 independent plas-
ma cytokines [IL-2, IL-6, TNF-α, IFN-γ, IL-4, 
transforming growth factor (TGF)-β] among 
healthy controls and suicidal and non-suicid-
al patients. They found that suicidal patients 
had lower IL-2 plasma levels compared to the 
other two groups. Also, lower IL-4 and high-
er TGF-β plasma levels were reported in both 
suicidal and non-suicidal patients than healthy 
controls. However, the independent studies in 
their sample did not show consistent results, 
which may be due to differences in phenotypes 
of suicidal behavior, difficulty in controlling 
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for confounders, differences in immunoassay 
techniques, and genetic and epigenetic effects. 
Further research is needed, as these heteroge-
neity-inducing factors might serve as medi-
ators or moderators between suicidality and 
inf lammation.
Cytokines as a Mechanism Affecting 
Brain Function and Behavior
An increase in cytokine levels is one of the 
suggested mechanisms behind the association 
between infection and increased risks of sui-
cide. Viral infection can activate Toll-like re-
ceptors (TLRs) that are known to play an im-
portant role in regulating immune responses43. 
Activation of TLRs induce a pro-inflammatory 
state and lead to the secretion of large amounts 
of inflammatory factors, such as IL-6, IL-12, 
IL-15, and TNF-α44. These changes in inflam-
matory cytokine levels can affect brain func-
tion and behavior.
They can enter the brain directly through 
a compromised blood-brain barrier (BBB), 
which is associated with increased CSF levels 
of glycosaminoglycan hyaluronic acid, indic-
ative of neuro-inf lammation45. Additionally, 
they communicate with the brain via several 
mechanisms, including the kynurenine path-
way, monoamine metabolism, and HPA axis8. 
Kynurenine Pathway
The kynurenine pathway is active in both 
the peripheral and central nervous system, in 
which indoleamine 2,3-dioxygenase (IDO) and 
tryptophan 2,3-dioxygenase (TDO) catalyzes 
the production of kynurenine from tryptophan. 
Among depressed patients, blood kynurenine 
levels are elevated in suicide attempters com-
pared with a depressed-only control group46. 
After production, kynurenine breaks down in-
to neuroactive compounds like quinolinic acid 
(QUIN) and kynurenic acid (KYNA). Inflam-
matory cytokines, such as IFN-γ, IL-6, and 
IL-1β activate these enzymes and thereby shift 
tryptophan metabolism towards an increase of 
QUIN47-49. 
QUIN is an N-methyl-D-aspartic ac-
id (NMDA) receptor agonist predominantly 
produced by microglia and macrophages50. It 
has agonistic effects on the NMDA receptor 
by acting through the NR1 + NR2A and the 
NR1 + NR2B subunits51,52. QUIN was found 
to increase reactive oxygen species (ROS) and 
neuronal glutamate release, and decrease glu-
tamate uptake and recycling by astrocytes, and 
increase astrocytic production of pro-inf lam-
matory cytokines53-55. KYNA, on the other 
hand, antagonizes the glycine co-agonist site 
of the NMDA receptor and is predominantly 
produced by astrocytes51. Besides the NMDA 
receptor, KYNA has also antagonistic effects 
on the AMPA receptor and α7 nicotinic acetyl-
choline receptor (α7nAChR)56, it is known to 
have neuroprotective and anticonvulsive prop-
erties57,58. 
QUIN levels were found to be associated 
with increased suicide risk and levels of in-
f lammatory cytokines, and the QUIN levels 
were increased in the CSF of suicidal patients59. 
In fact, QUIN levels were found higher in CSF 
of suicide attempters than in healthy controls. 
It was also positively correlated with IL-6 in 
CSF, suggesting the relationship between the 
activation of kynurenine pathway and active 
inf lammation60. Furthermore, after a 2-year 
follow-up period, QUIN levels were elevated 
among suicide attempters with high IL-6 and 
lower KYNA levels also found to be associat-
ed with the severity of suicidal ideation and 
depressive symptoms61. 
Monoamine Metabolism
Besides increasing kynurenine production 
by making IDO steal tryptophan from the se-
rotonin synthesis pathway, cytokines can de-
crease the production of serotonin40. Studies62 
relating to suicidal behavior have shown that 
there is an abnormality of the serotonin sys-
tem (e.g., decreased serotonin metabolites and 
increased serotonin receptors). Inf lammatory 
cytokines can affect these serotonin systems 
in many ways, and this might be one of the 
mechanisms that link inf lammation with sui-
cidal behavior63. It has also been demonstrat-
ed62 that serotonin in patients with suicidal 
behavior have a relationship between lower 
serotonin levels in the blood and suicidal be-
havior. This may result from the activation of 
cytokines, such as IL-1β and TNF-α, which 
have been shown to increase the expression 
of serotonin transporter, consequently reduc-
ing the levels of serotonin64. Taken together, 
the above studies suggest potential mediating 
mechanisms between inf lammatory responses 
and suicidal behavior may in fact stem from 
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the effects on serotonin levels. Further studies 
are needed to distinguish the strength of such 
effects as well as additional mechanisms in 
which the inf lammation-suicide relationship 
is inf luenced.
HPA Axis
IFN-α treatments have been demonstrated to 
activate the HPA axis by increasing the level of 
cortisol and adrenocorticotropic hormone levels. 
Such forms of HPA axis activation are associated 
with the onset of depressive symptoms compared 
to those who did not receive treatment65. In addi-
tion, a systematic review of HPA axis dysregula-
tion in association with various pathophysiologi-
cal processes including mood disorders and sui-
cidal behaviors, has reported HPA axis activity to 
be involved in suicide risk regardless of the pres-
ence or absence of other psychiatric conditions66. 
By contrast, cytokines have been shown to ac-
tivate the HPA axis, which induces a change in 
the levels of corticotropin-releasing hormone and 
cortisol that leads to detrimental effects on neu-
rons40. In one study67, administration of cytokines 
such as IL-1, IL-6, and TNF-α activated the HPA 
axis in both animals and humans. Likewise, pre-
vious literature has described cytokines to affect 
the neuroendocrine function through the increase 
of HPA axis activity, specifically with acute cyto-
kine administration associated with the increase 
in corticotropin-releasing hormone (CRH), ad-
renocorticotropic hormone (ACTH), and cortisol 
release. All these increases have been present-
ed in patients with depressive disorders68. This 
demonstrates cytokines activating HPA axis and 
its relevance to one’s suicidality.
Infection and Suicide
Infection induced inflammations may also in-
directly lead to suicidality. These infections can 
affect the brain directly or reach the brain through 
peripheral inflammation that generates molecular 
mediators like cytokines.
Compared to the general population, patients 
with chronic hepatitis C virus infection showed a 
higher prevalence of depression and suicide risk69. 
Okusaga et al70 showed that seropositivity for in-
fluenza A, B, and coronaviruses were related to a 
history of mood disorders. Also, seropositivity for 
influenza B was higher in patients with a history 
of attempted suicide. 
Lyme and associated diseases (LAD) are an-
other infections that are linked to suicidality and 
combined suicidal and homicidal tendencies in in-
dividuals after being infected71. It was found that 
chronic infections of Borrelia burgdorferi showed 
increased quinolinic acid in cerebrospinal fluid72. 
The risk for suicidality was increased in hu-
man immunodeficiency virus (HIV) infection 
and, according to the study by Serafini et al73, 
HIV patients’ prevalence of MDD, suicidal ide-
ation, and suicide attempts ranged from 14.0% to 
27.2%, 13.6% to 31%, and 3.9% to 33% respec-
tively. In addition, individuals with HIV have 
reported a consistent association between MDD, 
suicidal ideation, and poor quality of life73. Toxo-
plasma gondii is another pathogen studied in this 
field, and its latent infection was identified to be 
a risk factor of suicides and suicide attempts74. It 
is known that T. gondii alters the glutamatergic 
and dopaminergic neurotransmission by increas-
ing the levels of cytokines, QUIN, and dopamine, 
which may lead to suicidal behavior8. These kinds 
of neurotropic pathogens may induce severe psy-
chiatric symptoms, as they can directly invade the 
brain and induce neuroinflammation. 
According to Lund-Sørensen et al75, people who 
have had hospital contact due to infections had a 
more than 40% increased risk of death by suicide, 
even after controlling for the psychological effect 
of being hospitalized. Also, both peripheral and 
central nervous system infections were found to 
be related to increased suicide risk. Among those 
infections, the highest risk was found in patients 
with hepatitis infection and HIV infection or ac-
quired immune deficiency syndrome.
COVID-19 Infection Associated 
with Suicide
Our attention now turns to COVID-19 infection 
and suicide. We posit here the COVID-19 pandem-
ic could induce suicidal behavior through the inter-
action of many different factors (Figure 1). 
Considering infection factors, immune cell in-
fection and the recruitment of uninfected cells can 
induce massive inflammatory responses. In viral 
infections, host response and clearance generally 
depend on type I interferon (T1IFN) expression. 
Once the viral infection is sensed by pattern as-
sociated molecular patterns (PAMPs), expres-
sion of T1IFN, and pro-inflammatory cytokines 
(IL-1, IL-6, TNF-α through NFκB) increases76. 
Indeed, patients infected with COVID-19 have 
high amounts of IL-1β, IFN-γ, IP10, and MCP1, 
which may lead to Th1 cell response activation9. 
Suicide associated with COVID-19 infection
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Also, Th2 cytokines (e.g., IL-4 and IL-10) were 
increased in COVID-19 infection9. Like other in-
fections, an increase in these molecular mediators 
can affect the brain via the mechanisms men-
tioned above.
In addition, the neurotropic potential of COVID-19 
has been proposed. A recent review reported that 
25% of COVID-19 patients show neurological man-
ifestations77. In COVID-19 patients, neurological 
conditions like headache, dizziness, ataxia, seizures, 
and others have been observed78. These neurological 
symptoms seem to develop in more severe patients 
than in mild or moderate patients79. Also, brain tissue 
edema and partial neuronal degeneration were report-
ed based on autopsy80. 
For these reasons, COVID-19 has the possibil-
ity of inducing suicidal behavior through inflam-
matory mechanisms. Indeed, a case of suicide in 
COVID-19 patients without any respiratory symp-
toms or fever has been reported32. However, wheth-
er COVID-19 can directly invade the brain is still 
unclear, as COVID-19 patients with neurological 
symptoms showed low or undetectable COVID-19 
RNA levels in CSF81. Moreover, the meta-analy-
sis data about cytokines and COVID-19 infection 
study does not always exhibit the same tendency 
(Table I). Whilst it has indicated the relationships 
between lower IL-2 and suicidal behavior, most 
infections including COVID-19 showed increased 
IL-2 plasma levels. Importantly, while lower IL-
4 was reported in both suicidal and non-suicidal 
patients compared to healthy controls, COVID-19 
patients exhibited increased IL-4. Although IL-
1β and IL-6 displayed a similar tendency, further 
studies concerning inflammatory responses of sui-
cide itself and relationship in COVID-19 patients 
are now required. The neurotropic potential of 
COVID-19 should also be studied. Currently, there 
are very few studies on COVID-19 and related cy-
tokine aberration, and it is difficult to generalize 
aforementioned cytokine alteration in COVID-19 
infection. 
Conclusions
COVID-19 pandemic is a worldwide problem 
with a rising death count and outcomes related to it 
merit consideration, such as suicide. It can be postu-
lated that the kynurenine pathway, monoamine me-
tabolism, and HPA-axis affect brain functions and 
induce suicidal behaviors via cytokines produced by 
Figure 1. Hypothesized mechanisms underpinning suicidal behavior during pandemics essential inflammation-related clues. 
TLR, Toll-like receptors; IL-1β, interleukin-1β; IL-6, interleukin-6; IDO, indoleamine 2,3-dioxygenase; TDO, tryptophan 
2,3-dioxygenase; KYNA, kynurenic acid; QUIN, quinolinic acid; NMDA, N-methyl-D aspartic acid; AMPA, α-amino-3-hy-
droxy-5-methyl-4-isoxazole propionic acid; ROS, reactive oxygen species; HPA, hypothalamic-pituitary-adrena.
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Cytokines
Meta-analysis about cytokines and suicidal behavior Studies of cytokines and COVID-19 infection
Studies Study design Tendency Country Sample size Sample Studies Study design Tendency Country Sample size Sample
IL-1β Black et 
al41, 2015
Meta-analysis Increase U.S. 583 patients with suicidality,  
315 patients without suicidality, 
and 845 healthy controls
Plasma Huang et al9, 2020 Observation 
study
Increase China 41 patients diagnosed 
with COVID-19
Plasma
IL-6 Black et 
al41, 2015
Meta-analysis Increase U.S. 583 patients with suicidality,  
315 patients without suicidality, 
and 845 healthy control
Plasma Huang et al9, 2020 Observation 
study
Increase China 41 patients diagnosed 
with COVID-19
Plasma
Yanlei et al82, 2020 54 patients diagnosed
with COVID-19
IL-2 Ducasse et 
al83, 2015
Meta-analysis Decrease France 494 suicidal patients,  
497 non-suicidal patients  
and 398 healthy controls.
Plasma Huang et al9, 2020 Observation 
study
Increase China 41 patients diagnosed 
with COVID-19
Plasma
IL-4 Ducasse et 
al83, 2015
Meta-analysis Decrease France 494 suicidal patients,  
497 non-suicidal patients  
and 398 healthy controls.
Plasma Huang et al9, 2020 Observation 
study
Increase China 41 patients diagnosed 
with COVID-19
Plasma
TGF- β Ducasse et 
al83, 2015
Meta-analysis Decrease France 494 suicidal patients,  
497 non-suicidal patients  
and 398 healthy controls.
Plasma N/A N/A N/A N/A N/A N/A
COVID-19, coronavirus disease 2019. IL-1β, interleukin-1β. IL-4, interleukin-4. IL-6, interleukin-6. TGF- β, transforming growth factor-β. 
Table I. Cytokine alterations found among people with suicidal behavior and COVID-19 infection.
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COVID-19 infection. Though pandemics can serve 
as a significant environmental factor contributing 
directly to increased suicide risk, the role of inflam-
mation by an infection should not be overlooked.
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